| Truman Medical Center Lakewood Care Center | |
| 7900 Lee's Summit Road, Kansas City, Missouri 64139 | |
| (816) 404-7000 | |
| Name | Truman Medical Center Lakewood Care Center |
|---|---|
| Location | 7900 Lee's Summit Road, Kansas City, Missouri |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 188 |
| Occupancy Rate | 78.99% |
| Medicare ID (CCN) | 265845 |
| Legal Business Name | Truman Medical Center Incorporated |
| Ownership Type | Non Profit - Other |
| NPI Number | 1316082316 |
| Organization Name | TRUMAN MEDICAL CENTER, INCORPORATED |
| Doing Business As | UNIVERSITY HEALTH LAKEWOOD CARE CENTER |
| Address | 7900 Lees Summit Rd, Kansas City, MO 64139 |
| Phone Number | 816-404-7000 |
News Archive
"As we head into the time of year people usually associate with selflessness and giving, Canadians should stop and think about whether our country is doing enough for international development," Steven Hoffman, an assistant professor at McMaster University, a fellow at the University of Toronto and an instructor at the Harvard School of Public Health, writes in a Globe and Mail opinion piece.
"Given the increasingly aligned incentives" between the private sector and global health and development practitioners, "the time is right for more effective and consistent collaboration between these two groups," Dheeraj Batra, head of business design at IDEO Mumbai, and David Milestone, senior adviser at USAID's Center for Accelerating Innovation and Impact, write in a USAID "IMPACTblog" post originally published in the "Stanford Social Innovation Review."
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
Unitrin, Inc. said today that its previously announced negotiations with Physicians Mutual Insurance Company for the sale of Unitrin's Reserve National Insurance Company subsidiary have been terminated due to a failure by the parties to reach a definitive agreement.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
"As we head into the time of year people usually associate with selflessness and giving, Canadians should stop and think about whether our country is doing enough for international development," Steven Hoffman, an assistant professor at McMaster University, a fellow at the University of Toronto and an instructor at the Harvard School of Public Health, writes in a Globe and Mail opinion piece.
"Given the increasingly aligned incentives" between the private sector and global health and development practitioners, "the time is right for more effective and consistent collaboration between these two groups," Dheeraj Batra, head of business design at IDEO Mumbai, and David Milestone, senior adviser at USAID's Center for Accelerating Innovation and Impact, write in a USAID "IMPACTblog" post originally published in the "Stanford Social Innovation Review."
GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.
Unitrin, Inc. said today that its previously announced negotiations with Physicians Mutual Insurance Company for the sale of Unitrin's Reserve National Insurance Company subsidiary have been terminated due to a failure by the parties to reach a definitive agreement.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 4 |
| Total Amount of Fines in Dollars | $4875 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 4 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 1.85 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.93 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 24.01 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 10.1 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 6.4 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.34 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0.96 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.99 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 92.81 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.53 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 49.21 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 2.97 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 9.01 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 9.23 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.69 | 95.98 |